EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

A randomised, double‐blind, placebo‐controlled study to determine the analgesic efficacy, safety and tolerability of VPX638 administered topically to painful wounds

Jonathan Golledge iD, Sergio Parra, Pat M Aldons, Nicoletta Frescos, Rebecca K Iseli, Toni M Pardey, Casper F Pretorius, Omar R Shum iD, Paul A Yates, Cécile B Bascoul, Dannette K Doolittle, Ajay A Rege und 3 weitere

Wound Repair and Regeneration · 2025-01 · 33 (1)

DOI: 10.1111/wrr.70008 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Wound Repair and Regeneration, online erschienen am 12.02.2025. Verfasst von Jonathan Golledge und 14 weiteren Autor:innen. Beteiligte Einrichtung: Queensland Research Centre for Peripheral Vascular Disease, James Cook University and Townsville University Hospital and Australian Institute of Trop…. Hauptthemen laut MEDLINE: Analgesics, Pain, Wound Healing, Wounds and Injuries. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vapogenix, Heart Foundation, National Health and Medical Research Council, Queensland Government, Townsville Hospital and Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New analgesics are needed for painful wounds. Multiple reports suggest that topical sevoflurane may have analgesic effects. This placebo‐controlled randomised trial evaluated the analgesic efficacy and safety of VPX638 (topical sevoflurane). Seventy‐eight participants with painful wounds, were enrolled at eight Australian centres and randomly allocated to receive 2 × 5 mL of VPX638 ( N = 39) or placebo ( N = 40) during one wound dressing change. Numerical pain rating scores and use of opioids were recorded for 24 h. The primary endpoint was pain during wound cleaning, secondary endpoints evaluated pain for 24 h after drug application and opioids use. There was no significant difference in mean pain scores during wound cleaning between VPX638 and placebo (0.854; p = 0.23). The mean differences in summed pain intensity difference from baseline suggested VPX638 provided greater analgesia compared to placebo over 8 h ( p < 0.02), 12 h ( p < 0.01) and 24 h ( p < 0.05) and significantly longer duration of analgesia, 24.3 h for VPX638 versus 7.1 h for placebo ( p < 0.01). In the 24 h after drug administration, participants receiving VPX638 had a 50% decrease in opioid use over 24 h compared with placebo. VPX638 appeared safe and well‐tolerated. In conclusion, this small placebo‐controlled randomised trial suggested that VPX638 provides analgesia and is opioid‐sparing for up to 24 h after wound cleaning. It supports the need for further evaluation of the benefit of VPX638 as a topical analgesic for painful wounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnalgesicsPainWound HealingWounds and InjuriesAdultAgedFemaleHumansMaleMiddle AgedAdministration, TopicalAnalgesics, OpioidAustraliaBandagesDouble-Blind MethodPain ManagementPain MeasurementTreatment Outcome

Stichwörter der Autor:innen

analgesiapainsevofluranetopicalwound

Substanzen

AnalgesicsAnalgesics, Opioid

Autor:innen und Institutionen

  • Queensland Research Centre for Peripheral Vascular Disease, James Cook University and Townsville University Hospital and Australian Institute of Tropical Health and Medicine, Townsville, Queensland, Australia.
  • Vapogenix, Houston, Texas, USA.
  • The Prince Charles Hospital, Brisbane, Queensland, Australia.
  • Austin Hospital, University of Melbourne, Melbourne, Victoria, Australia.
  • The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Novatrials, Newcastle, New South Wales, Australia.

ORCID-Profile: Jonathan Golledge, Omar R Shum

Förderung

  • Vapogenix
  • Heart Foundation, National Health and Medical Research Council, Queensland Government, Townsville Hospital and Health Services

Zitieren

APA

Golledge, J., Parra, S., Aldons, P. M., Frescos, N., Iseli, R. K., Pardey, T. M., Pretorius, C. F., Shum, O. R., Yates, P. A., Bascoul, C. B., Doolittle, D. K., Rege, A. A., Thanawala, V. J., Giles, H., & Woodward, M. C. (2025). A randomised, double‐blind, placebo‐controlled study to determine the analgesic efficacy, safety and tolerability of VPX638 administered topically to painful wounds. Wound Repair and Regeneration, 33(1). https://doi.org/10.1111/wrr.70008

Vancouver

Golledge J, Parra S, Aldons PM, Frescos N, Iseli RK, Pardey TM, et al. A randomised, double‐blind, placebo‐controlled study to determine the analgesic efficacy, safety and tolerability of VPX638 administered topically to painful wounds. Wound Repair and Regeneration. 2025;33(1). doi:10.1111/wrr.70008

BibTeX
@article{Golledge2025,
  author = {Golledge, Jonathan and Parra, Sergio and Aldons, Pat M and Frescos, Nicoletta and Iseli, Rebecca K and Pardey, Toni M and Pretorius, Casper F and Shum, Omar R and Yates, Paul A and Bascoul, Cécile B and Doolittle, Dannette K and Rege, Ajay A and Thanawala, Vaidehi J and Giles, Heather and Woodward, Michael C},
  title = {A randomised, double‐blind, placebo‐controlled study to determine the analgesic efficacy, safety and tolerability of VPX638 administered topically to painful wounds},
  journal = {Wound Repair and Regeneration},
  year = {2025},
  volume = {33},
  number = {1},
  doi = {10.1111/wrr.70008}
}
Kostenlos starten →